Drug intelligence / Profile preview

kolopavivir

Development stage: Preclinical
Administration: Oral

Overview

Kolopavivir is an antiviral drug under investigation for the treatment of chronic hepatitis C virus (HCV) infection. It is being studied in combination with sofosbuvir, another direct-acting antiviral, as part of a real-world clinical trial evaluating its efficacy and safety for chronic HCV treatment. The precise mechanism of action, molecular class, and detailed pharmacology of kolopavivir are not specified in available sources. Its development appears to be focused on HCV rather than other viral infections[2].

Brand names: kolopavivir
Other names: kolopavivir

Beyond the preview

Go deeper on kolopavivir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kolopavivir.

Explore the full profile